|1.||Durnev, A D: 2 articles (11/2000 - 03/2000)|
|2.||Zhanataev, A K: 2 articles (11/2000 - 03/2000)|
|3.||Vakhrushev, Ia M: 1 article (01/2010)|
|4.||Khokhlacheva, N A: 1 article (01/2010)|
|5.||Palka, I P: 1 article (01/2009)|
|6.||Chichkanov, G G: 1 article (01/2009)|
|7.||Tsorin, I B: 1 article (01/2009)|
|8.||Seredin, S B: 1 article (11/2000)|
|9.||Seredenin, S B: 1 article (03/2000)|
|1.||Chromosome Aberrations (Chromosome Abnormalities)
03/01/2000 - "The chromosome aberration assay in the bone marrow cells of C57B1/6 mice showed that the new 2-mercaptobenzimidazole derivative afobazole(1-100 mg/kg) prevented manifestations of the clastogenic effects of dioxidine (100 mg/kg, i.p.) over a period of 24 h and reduced by 44-75% the cytogenetic effect of dioxidine (300 mg/kg, i.p.). "
11/01/2000 - "The influence of a new 2-mercaptobenzimidazole derivative afobazole on cytogenetic effects of dioxidine and cyclophosphamide was studied by counting chromosome aberrations in bone marrow cells of C57Bl/6 mice. "
01/01/2009 - "Experiments in narcotized rats showed the new selective anxiolytic afobazole, a derivative of 2-mercaptobenzimidazole, to cause a small bradycardia with almost no effect on the important parameters of heart hemodynamics and cardiac performance such as the arterial pressure, cardiac output, and mean aorta blood flow acceleration. "
05/01/1997 - "Experiments on anesthetized cats and rats showed that 2-mercaptobenzimidazole derivatives, known as SM-266 and SM-345, induced marked and long-term bradycardia, increased the stroke output, and reduced the requirements of the heart of oxygen. "